Background: The end-of-life (EoL) phase of care is inevitable for glioblastoma (GBM) patients; however, it lacks standardization. This study aimed to characterize the utilization of care at EoL in GBM patients, focusing on trends over time, regional variability, and the influence of socioeconomic factors.
Methods: This was a retrospective population-based cohort study of all patients with GBM treated in Ontario between 1994 - 2018 using administrative health data and registries available at ICES (formerly the Institute for Clinical Evaluative Sciences). The proportion of patients with palliative care, supportive care, and in-hospital deaths by year of diagnosis was estimated, and trends assessed with the Cochrane-Armitage trend test.
Results: The cohort included 9,013 GBM patients. There was an increase in supportive care components over the study time-period (29.6% in 1994 - 1998 to 60.2% in 2014 - 2018; p < 0.0001). There was a simultaneous decrease in in-hospital deaths (50.5% in 1994 - 1998 to 21.4% in 2014 - 2018; p<0.001) and hospitalizations within 30 days before death (65.5% in 1994-1998 to 51.7% in 2014 - 2018, p<0.001). This coincided with an increased in chemotherapy administration within 14 days of death and ICU admissions within 30 days of death over the studied period of time. Patient neighborhood income level and geographic location influenced EoL care patterns with regards to both supportive and aggressive components.
Conclusions: Over time there was an expansion of both inpatient and outpatient palliative care use at EoL. Rurality and neighborhood income quintile significantly influenced the utilization of these resources, underscoring the need for standardized EoL care practices.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/neuonc/noaf043 | DOI Listing |
Sci Adv
March 2025
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single tumor site. To investigate the GBM-specific 3D genome organization and its heterogeneity, we conducted Hi-C experiments in 21 GBM samples from nine patients, along with three normal brain samples.
View Article and Find Full Text PDFPurinergic Signal
March 2025
Université Côte dAzur, CNRS, INSERM, IRCAN, Nice, France.
Over the past few years, transcriptomics has emerged as a pillar for modern scientific research, enabling the comprehensive profiling of gene expression. The availability of large-scale public datasets, such as NCBI Gene Expression Omnibus, International Cancer Genome Consortium, and The Cancer Genome Atlas, has significantly boosted many scientific discoveries. However, to analyze and interpret these vast datasets, sophisticated bioinformatic tools are often necessary.
View Article and Find Full Text PDFActa Neurochir (Wien)
March 2025
Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", 80131, Naples, Italy.
Background: Inferior Fronto-Occipital Fascicle (IFOF) is a multitasking connection bundle essential for communication and high level mentalization. The aim of the present study was to quantitatively assess its radiological-anatomical-morphometric modifications according to different brain tumor histotype.
Methods: A retrospective multicentric Italian study was conducted.
Adv Healthc Mater
March 2025
Institute of Quantum Biophysics, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, characterized by its heterogeneity in cellular components, including reactive astrocytes and microglia. Since neuroimmune responses like astrogliosis and microgliosis gain recognition as vital factors in brain tumor progression, there is a growing need for clinically relevant models that assess the interactions between astrocytes, microglia, and GBM. Here, a NEuroimmune-Oncology Microphysiological Analysis Platform (NEO-MAP) is presented as a "new map" to observe astrocytic scar formation and microgliosis in response to GBM.
View Article and Find Full Text PDFCell Prolif
March 2025
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Glioblastoma multiforme (GBM) is the deadliest brain tumour with an extremely poor prognosis. Tryptophan catabolism could enhance an array of protumour-genic signals and promoted tumour progression in GBM. However, the mechanisms of oncogenic signalling under tryptophan catabolism and potential therapy targeting this pathway have not been completely understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!